Chaining up diarrhoea pathogens

Vaccinations are known to protect against pathogens such as bacteria or viruses. They direct the body to form protective antibodies (IgA), and have been successfully used against some intestinal infections.

However, exactly how intestinal antibodies – known as secretory IgA – protect against infections was previously unclear. A group of researchers led by ETH Senior Assistant Emma Slack, have now used the example of salmonella-based diarrhoea to show that secretory IgA works very differently to how we previously assumed.

In a study published recently in the journal Nature, the researchers showed that vaccine-induced IgA effectively “enchained” the pathogens in the intestine: IgA binds the bacteria’s daughter cells to each other during cell division. Although the enchained bacteria can continue to multiply, all their offspring remain trapped in these clumps. This clumping of genetically homogeneous bacteria prevents the attack of the intestinal tissue, accelerates the excretion of the pathogen and prevents genetic exchange between bacteria enchained in different clumps.

Agglutination only in the test tube

That antibodies and bacteria clump, a process known as agglutination, has long been known. However, this only occurs when antibodies and bacteria are present in high densities and so often come into contact with each other. “In the test tube, it happens in textbook fashion. There are high enough concentrations of antibodies and bacteria, so they often collide,” says Dr. Slack.

In the intestine, however, such high pathogen densities are the exception: “this makes it much less likely that the IgA-coated bacteria will collide,” explains Dr. Slack. Despite this, research has long observed that such clumps do form in the intestine – meaning there must have been another explanation for the clumping.

Bacterial growth controls clumping

Clumps hinder disease

“The clever thing about clump formation is that the antibodies don’t kill the bacteria, which in the worst case could lead to a violent immune response. They simply prevent the microbes from interacting with the host, among themselves or with close relatives,” says Wolf-Dietrich Hardt, Professor of Microbiology at ETH Zurich, who played a key role in the study.

Fighting intestinal infections using vaccination thus has several advantages: antibody-bacteria clumps cannot approach the intestinal wall, which prevents the intestinal mucosa from becoming inflamed. The intestine also gets rid of the clumps quickly, and after a few days they are cleared in the faeces. “The system is efficient. It is easier to get rid of a whole clump than to capture and eliminate many individual bacterial cells,” says Dr. Slack.

No exchange of resistance genes

Intestinal vaccination could help to overcome the antibiotic resistance crisis. Vaccination decreases the incidence of diseases potentially requiring antibiotic usage, which would automatically reduce the development and spread of resistance to antibiotics. IgA-driven clump formation also directly prevents genetic exchange between individual captured bacterial populations. Bacteria often exchange genes in the form of plasmids (ring-shaped DNA molecules), which frequently carry the feared antibiotic resistance genes. To exchange plasmids, however, the bacterial cells have to touch, which they can’t do if they are stuck in separate clumps.

Livestock vaccination

The researchers used oral vaccines made from killed salmonella and E. coli bacteria. They suggested that this strategy could also be used against the pathogens of other intestinal diseases such as Shigella or Listeria.

The largest area of application for salmonella vaccination could be in farm animals such as pigs, which often act as a reservoir for antibiotic-resistant pathogens. Humans can become infected by contact with these animals and their raw meat. A vaccination for humans could also be feasible, which would benefit people working in disaster or epidemic areas, or those travelling in regions where bowel infections are common.

Extensive collaboration needed

The present study is the result of a more than six-year collaboration between researchers from several ETH departments and institutions such as ScopeM, and other university institutions including the Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland, the University of Melbourne, Australia, and CNRS - UPMC, France. Collaboration with engineers such as Douglas R. Brumley and Roman Stocker was critical for the discovery of the enchainment mechanism.

Emma Slack leads a group at ETH Zurich’s Institute of Microbiology. In 2011, she received an Ambizione grant from the Swiss National Science Foundation (SNSF) and began her work in Wolf-Dietrich Hardt’s research group.